HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

PeopleandPicks.com is Zacks' Community Website
Find great stocks and great stock pickers in our online community. It's social, it's profitable and it's Free! Join the fun at PeopleandPicks.com
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Top 10 Stocks
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


PRX: Par Pharmaceutical Cos Inc - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

PAR PHARMACEUTICAL COS INC (NYSE)
PRX 24.13 0.06 (0.25%) Vol.  38,582 09:48 ET

Day Low - High 23.83 - 24.18
52wk Low - High 8.57 - 27.93
Avg Volume 386,750
Industry MED-GENERIC DRG
Market Cap 838.09 M
Div - Yield 0.00 - 0.00
PE (forward) 13.99
PEG Ratio .27
Current Year Est. 1.72
EPS Last Year 2.12
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Buy12%
# 2Strong Sell50.23%
# 3Hold14%
# 4Sell3.97%
# 5Hold1.85%
S&P50012.22%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


downgraded 02/09/2010
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 02/08/2010
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
PAR PHARMACEUTICAL COS INC PRX PREMIUM
DOCTOR REDDYS RDY PREMIUM
IMPAX LABORATRS IPXL PREMIUM
MYLAN INC MYL PREMIUM
See all MED-GENERIC DRG Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.86
ABR (Last Week) 1.86
# of Recs in ABR 7
Average Target Price 30.40
Industry Rank by ABR 136 out of 217
Rank in Industry 5 out of 11
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate PRX?
Buy
Sell
Find out what the Zacks Community
thinks of PRX at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR PRX
Zacks Equity Research: Report for PRX
Feb 08, 2010
Zacks Blog: Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Inc., Teva, Mylan, Dr. Reddy’s and Par Pharma
Jan 15, 2010
Zacks Blog: Watson Set to Top Expectations
Jan 14, 2010
Zacks Blog: Neutral on Watson
Jan 08, 2010
Zacks Blog: Neutral on Santarus
Jan 06, 2010
Zacks Blog: Zacks Releases Four Powerful ''Buy'' Stocks: American Superconductor Corp, Wolverine World Wide Inc., Par Pharmaceutical Cos. and Jones Apparel Group Inc.
Dec 04, 2009
Momentum: Par Pharmaceutical Cos.
Dec 04, 2009
Zacks Blog: Zacks Releases Four Powerful ''Buy'' Stocks: Cantel Medical Corp, Avon Products Inc., Bio-Rad Laboratories, Inc. and Par Pharmaceutical Companies, Inc.
Oct 20, 2009
More Zacks Commentary
NEWS
SmarTrend's Trend Spotter See Continued Downward Momentum on Shares of Par Pharmaceutical (PRX)
Feb 09, 2010
Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
Feb 05, 2010
Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2009 Results on February 24, 2010
Feb 02, 2010
SmarTrend's Candlestick Scanner Detects Bearish Dark Cloud Cover Pattern for Par Pharmaceutical (PRX)
Jan 29, 2010
Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Inc., Teva, Mylan, Dr. Reddy's and Par Pharma
Jan 15, 2010
MonoSol Rx and Strativa Pharmaceuticals Extend Strategic Relationship
Jan 05, 2010
Zacks Releases Four Powerful ''Buy'' Stocks: American Superconductor Corp, Wolverine World Wide Inc., Par Pharmaceutical Cos. and Jones Apparel Group Inc.
Dec 04, 2009
Conference Calls Today: 9 A.M. EDT
Dec 03, 2009
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate 0.57 0.50 2.48 1.72
Number of Estimates 7 4 7 7
Low Estimates 0.46 0.42 2.35 1.51
High Estimate 0.70 0.58 2.60 2.00
Year Ago EPS 0.21 0.49 0.05 2.48
EPS Growth 172.79% 2.55% 4865.71% -30.72%

More Estimates

COMPANY DESCRIPTION
Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical, Inc. Through its FineTech subsidiary, Par also develops and utilizes synthetic chemical processes to design and develop intermediate ingredients used in the production of finished products for the pharmaceutical industry.

Full Company Report
FINANCIALS
EPS TTM 2.12
Sales 578.11
Net Income 34.28
Price/Earnings 11.35
Price/Book 1.73
Price/Cash Flow 24.22
Price/Sales .79


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2010 Zacks Investment Research